Statement Of Cash Flows [Abstract]

Alligator Bioscience - Filing #703045

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	—	141 736 SEK	141 736 SEK	143 296 SEK	—	143 296 SEK	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for depreciation and amortisation expense	—	11 144 SEK	—	—	—	11 522 SEK	—
Adjustments for share-based payments	—	4,000 SEK	—	—	—	42,000 SEK	—
Other adjustments for non-cash items	—	65,000 SEK	—	—	—	- SEK	—
Interest paid, classified as operating activities	—	235,000 SEK	—	—	—	347,000 SEK	—
Interest received, classified as operating activities	—	- SEK	—	—	—	218,000 SEK	—
Cash flows from (used in) operating activities	—	127 033 SEK	—	—	—	141 352 SEK	—
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities	—	45,000 SEK	—	—	—	102,000 SEK	—
Cash flows from (used in) investing activities	—	45,000 SEK	—	—	—	156 886 SEK	—
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	—	342 665 SEK	—	—	—	- SEK	—
Repayments of borrowings, classified as financing activities	—	301,000 SEK	—	—	—	354,000 SEK	—
Payments of lease liabilities, classified as financing activities	—	6 672 SEK	—	—	—	5 794 SEK	—
Cash flows from (used in) financing activities	—	301 795 SEK	—	—	—	6 148 SEK	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	—	60,000 SEK	—	—	—	145,000 SEK	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	—	174 717 SEK	—	—	—	9 386 SEK	—
Cash and cash equivalents	278 148 SEK	—	—	—	103 342 SEK	—	93 890 SEK